Vertex Pharmaceuticals ( VRTX 2.72%) had a fine Tuesday on the stock exchange. The biotech 's shares closed the day nearly 3% ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

GOOGL's first-quarter 2025 results are likely to reflect strength in Generative AI, search, and cloud amid rising cloud ...

The theme of today's Connections puzzle is how you interact with certain words, making them tricky to put together without ...

Southeast Asia’s (SEA) entrepreneurial landscape, backed by its flourishing technology startup ecosystem, is primed to ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals got a healthy boost on Tuesday, with shares climbing nearly 3% thanks to a double dose of analyst ...

CRISPR and CRISPR-Associated Gene Market Set to Surge to $20 Billion by 2035, Fueled by Technological Breakthroughs and Biotech Investments The global CRISPR and CRISPR-Associated Gene Market Size is ...

Healthcare providers and artificial intelligence vendors have touted AI’s potential to automatically interpret medical test ...